Marimed (MRMD) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 4, 2026, to be held virtually, with voting and Q&A available online.

• Record date for voting is April 10, 2026; 398,920,671 common shares and 26,900,000 Series B Preferred Shares outstanding, with only common shares eligible to vote.

• Proposals include election of four directors and advisory approval of independent auditors for 2026.

• Proxy materials, including the annual report, are available online for shareholder review.

Voting matters and shareholder proposals

• Shareholders will vote on electing four directors and on the advisory approval of M&K CPAs PLLC as independent auditors for 2026.

• Only the auditor approval is considered a routine matter for broker voting discretion.

• Shareholder proposals and nominations for the 2027 meeting must be submitted between November 24 and December 24, 2026, for proxy inclusion.

• Additional proposals for the 2027 meeting not in the proxy must be submitted between February 4 and March 6, 2027.

Board of directors and corporate governance

• Board consists of four directors: Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.; all are current members and nominees.

• Three standing committees: Audit, Compensation, and Nominating & Governance, all comprised of independent directors.

• Board leadership structure features a non-executive chairman and separate CEO, with regular evaluation of structure and risk oversight.

• Directors are encouraged to attend annual meetings; all attended at least 75% of meetings in 2025.